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ABSTRACT
This article is part of a series of manuscripts dealing with
the incorporation of patient-reported outcomes (PROs) into
clinical trials. The issues dealt with in this manuscript
concern the common pitfalls to avoid in statistical analysis
and interpretation of PROs. Specifically, the questions ad-
dressed by this manuscript involve the analysis pitfalls with
PRO data in clinical trials and how can they be avoided (e.g.,
missing data, multiplicity, null results etc.). The manuscript
provides key literature for existing resources and proposes
new guidelines.
Keywords: clinical significance, minimally important differ-
ence, missing data, patient-reported outcomes, statistical
analysis.
Introduction
This article deals with issues of statistical analysis
and interpretation of patient-reported outcome (PRO)
data. The primary focus and context relate to support-
ing a labeling or advertising claim of a PRO benefit for
a new or approved pharmaceutical product. The issues
we discuss are not unique to pharmaceutical and regu-
latory applications, so the information may be gener-
alizable to other clinical trials of other medical
interventions involving PRO end points. For this
article, we are assuming that the PRO is an important
effectiveness end point in the study and that the intent
of the research program is to achieve a labeling or
promotional claim. We are also assuming that the
PROs were selected based on a strong rationale, are
credible, are appropriate, and have evidence support-
ing systematic development and psychometric qualities
in the particular study population [2]. Other articles in
this series focus on best practices for PRO instrument
development and psychometric evaluation [3–9].
In addition, we think that achieving a PRO claim
must require the a priori specification of a statistical
analysis plan. We do not endorse basing a PRO claim
on a post hoc analysis. The statistical analysis plan
should be prescriptive and restrictive in terms of the
analysis undertaken. The statistical analysis plan
should detail the methods for handling missing data,
multiplicity, and other relevant issues associated with
the PRO data analysis. Any post hoc analysis that
produces supplementary results should be considered
interesting findings that should be confirmed in future
studies.
This article focuses on four major areas related to
statistical analysis of PRO data. In the first section of the
article, we deal with commonly seen pitfalls including
missing data, multiplicity of end points, blinding,
choosing the correct end point for analysis, and the role
of sensitivity analyses. In the second section, we discuss
what to do when results turn out to be nonsignificant.
What Are the Analysis Pitfalls with PRO
Data in Clinical Trials and How Can They
Be Avoided?
Missing Data
Much has been written about missing data and the
analysis of PRO data [10–13]. Several methodological
approaches have been proposed and tested in clinical
applications in recent years. Missing data can have two
major impacts on statistical analysis of clinical trials
data. At a minimum, the missing data can produce
wider confidence intervals and reduced statistical
power to detect a treatment effect. At worst, missing
data can distort treatment effects. The present recom-
mended practice is to assess the degree to which
missing data may affect the results of the clinical trial
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and thereby be considered “nonignorable” [13]. The
primary goal of analyzing missing data is to consider
whether a systematic influence or covariate could
have introduced bias into the analytical results. For
example, missing data closely linked to patients’ health
and PRO may bias the estimates of treatment effect.
Wherever possible, the source of the missing data
should be uncovered so that the study data set is as
complete as possible and scientifically supportable.
Data cleaning for PRO assessments should be handled
in the same way an analyst would handle a missing
laboratory test or clinical measure.
The best solution for missing data is, of course, to
avoid missing data entirely by obtaining perfect com-
pliance with protocol data collection requirements.
Although this ultimate goal is not realistic, the amount
of missing data can nonetheless be minimized by
simple methodological practices. These include:
1. Treat PROs like any other end point in the trial.
The PRO end points should be integrated into the
data collection and clinical trial protocol. The
PRO measures should not be seen as an additional
burden but rather as a vital part of the scientific
goals of the study.
2. Identify key personnel to oversee and coordinate
the PRO aspects of the trial and serve as sounding
boards and feedback experts for the trial.
3. Assure that the PROs will be administered in a
standardized fashion in all study sites. Training of
study site personnel in the administration of PROs
and in the review of completeness of PRO mea-
sures is essential.
4. Consider the presentation format and patient
burden of PRO data collection instruments from
the patient perspective. Would they want to answer
all these questions? Is there anything confusing,
invasive, controversial, unnecessary, unclear, or
omitted? Make the PRO instrument professional-
looking and consider the formatting and appear-
ance of the data collection instruments.
How much missing data renders various forms of
imputation and statistical analysis invalid? Fairclough
[10] and others have indicated that if more than 50% of
the data for a particular end point is missing, then any
analysis likely should not be undertaken because the
analysis will be based on as much data present (with
error) as are missing been acquired. If between 20% and
50% of data are missing for an end point, the analysis
can be seriously compromised, but it can still be under-
taken with a thorough checking of underlying analyti-
cal assumptions and extensive sensitivity analyses. If
fewer than 20% of the data are missing for an end point,
there may not be a major impact on study findings, but
caution should still be employed and selected sensitivity
analyses are recommended. If the amount of missing
data is below 10%, the potential bias is slight and a
simple imputation approach may be sufficient. The
amount of missing data anticipated may influence the
choice of PRO instruments and/or the PRO end point
definitions.
Statistical analyses should be based on all of a sub-
ject’s available data. Under no circumstances should
only complete cases be used in an analysis; numerous
studies have demonstrated that patients who provide
complete data tend to be the “best performers” with
better PRO scores than are representative of the
general population [10,14]. Therefore, if a subject has
data missing on the entire questionnaire on a particu-
lar occasion, that subject can still contribute on other
occasions when her scores are available. If a subject
discontinues or drops out of the study, the end of
treatment visit data should be used as the subject’s
final assessment. We next discuss handling missing
items within a PRO assessment and handling missing
forms for individual patients.
Missing Items within a PRO Assessment
The handling of missing items on a particular question-
naire should be based on the recommendations given in
the scoring manual of that questionnaire or, if not
provided, by other forms of guidance (e.g., email or
phone correspondence) from the developer of that ques-
tionnaire. If those recommendations are not available,
missing items can be imputed for multiitem scales by
considering alternative approaches. For example, if
at least half of the items from the scale have been
answered, one alternative approach is to assume that
the missing items have values equal to the average of
those items that are present for the respondent [15]. For
instance, role functioning and cognitive functioning of
the European Organization for Research and Treat-
ment of Cancer (EORTC) each contain two items; thus,
analysts can estimate these scales whenever one of their
constituent items is completed. Physical functioning
(PF), by contrast, contains five items, so at least three
items need to be completed. For example, if only Ques-
tion 3 (Q3) is missing on PF, then we would compute the
Raw Score and PF Score as follows:
Raw Score Q Q Q Q= + + +( )1 2 4 5 4
PF Score Raw Score
Raw Score
= − −( )[ ] ×
= −( ) ×
1 1 1 100
2 100
This approach is algebraically equivalent to using
all items that were completed. In other words, the
missing items are simply ignored when making the
calculations. Otherwise, the subscale score must be
considered missing.
Occasionally, using common logic, it is acceptable
to complete an individual assessment form on behalf of
the respondent, but this must be done transparently
(i.e., reported) and with sound scientific rationale. For
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example, in the McCorkle Symptom Distress Scale,
there are two items for nausea; one for frequency and
the other for severity. Patients without any nausea
commonly indicate so on the frequency item and then
leave the intensity item blank. In this situation inves-
tigators can reasonably complete the intensity item as
indicating the lowest possible score as that conclusion
is clearly logical. We recommend that these logic-based
imputation methods be specified a priori in the
protocol.
Missing Forms for Individual Patients
Investigators should summarize the total number (and
percentage) of and reasons for missing forms by treat-
ment. The analysis should be based on all available
observations during the treatment period. The
repeated measures, mixed effects model, which consid-
ers all measurements across time for each subject, can
provide a simple yet sensible approach to address
missing PRO data [11,16–18]. The validity of this
model is based on the assumption that the missing data
are missing at random, conditional on both model
covariates, and observed values of the dependent vari-
able. Under this assumption of ignorable nonresponse,
statistical tests from the mixed effects model are
expected to be valid and unbiased. Even when the data
may not be entirely missing at random, results from a
mixed effects model analysis of repeated measures may
be quite robust when observed covariates, such as
baseline score on the PRO assessment which may
explain much of the missing data, are included [13,19].
To examine the association of missing data with
observed changes in the PRO scores, analysts should
include dropout patterns and depict average PRO
scores stratified by time of dropout (by treatment and
across treatments) [13]. These dropout patterns can be
coupled with the descriptive profiles on the total
number (and percentage) of and reasons for missing
forms, to provide a better understanding of the mecha-
nisms for missing data. These analyses can assist in
determining whether the missing PRO data are most
likely ignorable or nonignorable. We also recommend
examining baseline demographic, clinical, and PRO
differences between those subjects providing complete
PRO data and those subjects with various amounts of
missing data.
If the difference in the proportion of dropouts (and
reasons for dropout) between treatment arms is sub-
stantial over time, results of the repeated measures
model should be extended with those from a pattern
mixture model. This is a more complicated model than
the mixed effects model and it does not assume an
ignorable missing data mechanism [11,13,17]. With a
pattern mixture model, parameter estimates can be
obtained by averaging over the missing data patterns.
When there are nonignorable missing data, the recom-
mendation is to use a pattern mixture model as the
primary model [20] with a standard mixed effects
model and other selected sensitivity analyses.
Resources for understanding and implementing
mixed models and other statistical techniques are
covered by Fairclough [10,21], Troxel [22], Fayers and
Machin [23], Lenderking and Revicki [24], and
Molenberghs and Verbake [25]. Also, guidelines
regarding handling missing PRO data in statistical
analyses are presented by Fayers and Hays [26], Fayers
and Machin [23], Troxel [22], Fairclough [27], and
Huntington and Dueck [14]. Revicki and Fairclough
[28] cover methods for minimizing missing data in
clinical trials.
Additional Ways to Handle Missing Data
In this section, we cover methods for handling missing
data. Particularly, we cover the intention to treat (ITT)
principle, the use of summary statistics (e.g., composite
end points, indicator variables, and area under the
curve [AUC] analysis), and imputation methods.
Intention to Treat Principle
Missing data may be handled analytically by the ITT
principle or by the modified ITT principle in which at
least one post-treatment measurement is required.
Intention to treat reduces the amount of missing data
or removes the issue entirely by labeling an individual
as a success or failure once they have initiated treat-
ment, regardless of whether they completed the trial.
In the following example, we translate the ultimate
PRO outcome into a binary (dichotomous) outcome.
In a trial of erythropoietin alpha [29] for improving
hemoglobin [30], patients were scheduled to receive
EPO for 16 weeks. Key end points were whether or not
a patient achieved a specified clinically important
increase in overall quality of life (QOL) from baseline
as measured by a simple linear analog. All patients
were evaluable for the PRO end point if they initiated
treatment. If they failed to provide data for a given
week, they were declared a treatment failure for that
week. Unless an observed clinically meaningful
increase in QOL was observed after baseline, the
patient was declared a treatment failure. Complete
data were obtained for this end point even though
some patients had intermittent missing data.
Summary Statistics
Missing data can be handled by scientifically credible
summary statistics. Summary statistics provide a
method to combine available data into an overall end
point. In anorexia trials, for instance, the maximum
patient-reported improvement in appetite over a
study period can be used as an end point to remove
missing data issues. As another example, the Ameri-
can College of Rheumatology (ACR) response criteria
constitute a composite end point developed as a
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primary end point for clinical trials comparing rheu-
matoid arthritis treatments [31,32]. The response
criteria combine clinical and PRO measures, includ-
ing number of swollen and tender joints, patient-
rated disease activity, clinician-rated disease activity,
patient-rated pain, Health Assessment Questionnaire
(HAQ), and c-reactive protein (CPR) values.
The scientific veracity of using summary statistics is
well validated and must be identified a priori. It should
also have evidence supporting reliability and validity in
the target indication. The composite end point has to
be validated by some reasonable scientific approach
and not just concocted de novo. Going through a
rigorous procedure including appropriate professional
input and scientific scrutiny is essential to the develop-
ment of any summary statistic. Summary statistics in
general may be difficult to interpret because they typi-
cally lack a natural conceptualization of what is mean-
ingful for what are essentially artificial summary
indices.
An indicator variable is another type of summary
statistic indicating whether a specific benchmark has
been achieved (such as an a priori specified clinically
meaningful benefit). Indicator variables produce com-
plete data and binomial variables for which a standard
statistical methodology such as Fisher’s exact test and
logistic regression readily apply. This is a preferred
approach where applicable because it requires distinct
a priori scientific justification for the handling of
missing data and produces an appealing analytical
approach. Unfortunately, the advantages of the binary
approach come at the possible expense of loss of
information.
Counterarguments to using this dichotomization
approach of success and failure is that it loses the
statistical power of the continuous end points. The key
issue is whether the information gleaned from the PRO
is sufficiently precise to be used as a continuous vari-
able or whether the perceived level of accuracy is
merely artificial numeritization. For example, the use
of linear analog response scales data measured to the
nearest hundredth of a millimeter is inappropriate
because people are barely accurate to the nearest mil-
limeter in responding to such items.
Area under the curve summary statistics are pro-
duced by combining longitudinal data into a simple,
single numerical entity. At its simplest level the AUC
represents the average value of the PRO over time for
the entire treatment period. Some approaches use
various distributional assumptions such as exponential
decay between time points or the trapezoidal rule in
estimating values between adjacent assessments. The
justification for alternative assumptions needs to be
based on scientific principles a priori rather than data-
based post hoc determination.
Sloan [33] and Huntington and Dueck [14] pro-
vide examples of the technique in general. Sensitivity
analysis is indicated if the distributional assumptions
are questionable. Typically, the assumptions do not
strongly affect the treatment comparison and so a
small number of alternative assumptions can be tested
before the consistency of the results becomes obvious.
Missing data are handled in AUC construction in
many ways, but typically by nearest-neighbor imputa-
tion or simply by constructing the AUC curve using the
available data and prorating via the proportion of
reporting periods.
Imputation Methods
In this section, we discuss single and multiple imputa-
tion methods. Single imputation is substituting a single
value for each missing value in a data set. On the other
hand, multiple imputations involve substituting several
values for each missing value; in essence, creating mul-
tiple data sets. The statistic of interest is computed for
each imputed data set and a final estimate is computed
by combining estimates across the multiple data sets
with readily available formulas in the multiple impu-
tation literature.
There are many methods for selecting the values to
impute whether using single or multiple imputation.
Despite the myriad imputation techniques available,
there is no uniformly accepted approach for imputa-
tion. All imputation methods are heavily reliant upon
the underlying assumptions of the analytical tech-
nique. Results of any technique hence can be as much
a result of the underlying assumptions as the true
empiric result. Regardless of the technique, all
methods involve statistically “guessing” what a per-
son’s PRO result would have been had it been
observed. As such, imputation is “fudging the
numbers” at its core. It is important to keep this truism
in mind as alternative methods for imputation are
considered to minimize the artificiality of the final
results.
Sloan [33] provides examples of how different
methods of handling missing data can provide star-
tlingly different PRO average profiles over time. The
most important issue is not the individual average
profile, however, it is the relative difference between
treatment regimens that is impacted by such missing
data. More often than not (though definitely not in all
cases), the missing data will impact both treatment
average profiles similarly, keeping the comparative
analytical results the same.
We recommend a differentiation between patients
who do not provide PRO data because of death and
those who do not provide data because of other
reasons (e.g., missing pages in booklet, dropped study
because of toxicity, etc.). Investigators should specify
ahead of time how they will handle data for patients
who die during the study; this permits them to examine
this group of patients separately from those who were
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potentially available to provide data at any given point
but failed to do so. Imputation of zeroes (or the lowest
possible score for a PRO) for those who have died, for
example, is a technique in applying the intention to
treat principle to patient PRO data but may result in
significant bias in the presence of large amounts of
missing form data [34]. Diehr and colleagues provide
other approaches to incorporating mortality into PRO
end points [1,35].
We do not endorse any particular method of impu-
tation as being applicable to all situations; neither do
we believe that any given method is prohibited in a
specific circumstance. Each study should have an
appropriate rationale that considers the expected
pattern of missing data and imputation method
chosen.
Single Imputation
The most common missing data approach in labeling
claims is to use last-value carried forward in which the
last observed value is substituted in for all subsequent
missing data values. This method has been criticized
for various reasons [24]. Alternative approaches in-
volve imputing the average-value carried forward, the
minimum or maximum value, or even imputing a zero
value for patients who have died. This last approach has
not seen much use but has the advantage of reflecting
the average value for the complete sample that initiated
the study. Some have argued that imputing a zero value
for death may be inaccurate for a number of reasons
[35]. The authors recommend that a single simple impu-
tation method be specified for the primary analysis and
justified within the context of the study.
Sensitivity analyses should include up to three dif-
ferent imputation approaches to verify that the results
of the primary analysis are credible. If the results are
not comparable, then this indicates the need for more
complex missing data modeling and may suggest
uncertainty regarding the PRO results.
Multiple Imputation
The use of complex statistical models to impute several
values for missing data has become the topic of many
statistical articles in recent years [21,22]. Whether
linear and nonlinear models provide any better scien-
tific “guesses” at missing numbers than common sense
and single imputation has yet to be shown. The gains
in terms of statistical power likely do not balance the
amount of work and the number of strong distribu-
tional assumptions that are required. Nevertheless,
because of the error inherent in “guessing,” multiple
imputations have the benefit over single imputation of
a built-in measure of added variability in estimates
computed from imputed data. (In multiple imputa-
tions, the estimation process considers the variability
of estimates across the imputed data sets.) This benefit
again likely does not balance the amount of work and
required strong distributional assumptions because
the added variability because of imputation can be
assumed small if imputing for a small percentage of
data and the simpler single imputation method is
chosen appropriately.
In essence, if the multiple imputation methods
provide a different answer than the simple single impu-
tation methods, investigators may not know whether
this is a result of improved precision or difference in
technique. Recent literature has demonstrated that the
result differs little across approaches [36].
Multiplicity
Analyzing multiple end points can be handled post hoc
statistically or a priori scientifically. Although dealing
with issues in the initial protocol is preferable, it is
reasonable to expect that some issues are best
addressed by statistical correction. We recommend,
however, that investigators still prespecify the use of
statistical correction in their statistical analysis plans.
Many PROs, particularly those that assess health-
related QOL or multiple facets of a disease are, by
nature, multidimensional. Other clinical end points
(such as tumor response) are also inherently multidi-
mensional but have been worked into acceptable,
agreed-upon single end points (e.g., a 50% reduction is
a response). For example, trialists do not report
average tumor size reduction or describe the charac-
teristics associated with tumor response.
The best way to deal with multiplicity is to define in
advance in the protocol or statistical analysis plan the
PRO domains that the treatment is expected to affect
and the domains that are not expected to be affected.
Any given treatment is unlikely to affect any disease
condition uniformly across all PRO subdomains. Addi-
tionally, in health-related QOL some dimensions may
not change with treatment, such as concern about
having a disease. These situations are analogous to the
expectation that each treatment will produce variable
toxicity profiles or disease-free survival, but not overall
survival, may be affected. In all such situations, the end
point of interest must be decided in advance and based
on scientific evidence. We and others [37] recommend
selecting a small number of PRO end points as being of
primary interest and viewing remaining domain scores
as secondary and supportive end points.
Multiple end points can be handled statistically by
comparison-wise corrections to the Type I error rates.
All these methods require an expanded sample size to
account for multiple testing over and above what
would be required for a single hypothesis test. The
Bonferroni approach is most common; in it, the
comparison-wise level of significance is set by dividing
the number of tests involved into the overall
experiment-wise Type I error rate. For example, if four
PRO domains are to be tested, then an overall 5%
Type I error rate is obtained if each test is carried out
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at the 5%/4 = 1.25% significance level. This approach
is considered quite conservative. Modifications of the
Bonferroni approach involve specific algorithms of
ordered testing, referred to as step-down, step-up, or
hierarchical analyses [38,39].
Multiple End Points for Label Claims
Repeated or multiple testing of outcomes (or even of
the same outcome at different times) will inevitably
result, incorrectly, in a statistically significant treat-
ment difference (say, P-value < 0.05) when no true dif-
ference exists between the treatments. Two forms of
multiplicity exist. One form is multiple testing of mul-
tiple domains at the same time; a case in point is
comparing multiple domains of the EORTC between a
pair of treatments at week 12. Another form is mul-
tiple testing of a given domain at multiple times; com-
paring the emotional function domain of the EORTC
between a pair of treatments at weeks 3, 6, and 12
illustrates this point.
Addressing the multiplicity of end points and time
points is contingent upon study objectives and hypoth-
eses, so no one definitive strategy for addressing mul-
tiplicity can be said to be appropriate for all studies.
Nonetheless, general guidelines can be offered that are
consistent with the specific hypotheses with regard to
the domain(s) and the time point(s), both of which
should be specified in advance. For a label claim, the
number of prespecified domains of primary interest
should be limited to no more than five and preferably
to no more than three domains [23]. The number of
key time points should also be limited and prespecified
to testing treatment differences at no more than two
time points for the primary analysis.
Suppose the objective is to show whether treatments
differ in the mean change score from baseline to week
12 in five particular domains. Three types of alpha or
P-value adjustments are recommended: 1) Bonferroni;
2) Bonferroni-Holm (Step-Down) Procedure; and 3)
Hochberg’s (Step-Up) Method. Of the three, Hoch-
berg’s Method is generally preferred. The following
example illustrates testing for treatment differences in
K = 5 domains where the five P-values are 0.20, 0.006,
0.011, 0.018, and 0.021.
Bonferroni:
If P(i) > a/K, then accept the null; if P(i)  a/K,
then reject the null.
Ordered
P-values:
P(1) = 0.006 P(2) = 0.011 P(3) = 0.018 P(4) = 0.021 P(5) = 0.20
a/K: a/5 = 0.01 a/5 = 0.01 a/5 = 0.01 a/5 = 0.01 a/5 = 0.01
Decision: Reject Accept Accept Accept Accept
“Reject” means reject the null hypothesis that no
treatment difference exists and therefore conclude that
a treatment difference exists. “Accept” means do not
reject the null hypothesis that no treatment difference
exists and therefore conclude that no treatment differ-
ence exists.
Bonferroni-Holm (Step-Down) Procedure [38]:
• Step-Down: Start with smallest P-value.
• If P(1) > a/K, then accept all null hypotheses (no
treatment effects) and stop.
• If P(1)  a/K, then the first null hypothesis [cor-
responding to P(1)] is rejected and then compare
P(2) with a/(K - 1).
• If P(2) > a/(K - 1), then accept all remaining null
hypotheses and stop.
• If P(2)  a/(K - 1), then the second null hypoth-
esis [corresponding to P(2)] is rejected and then
compare P(3) with a/(K - 2).




P(1) = 0.006 P(2) = 0.011 P(3) = 0.018 P(4) = 0.021 P(5) = 0.20
a/K,a/
(K-1),. . . =
a/5 = 0.01 a/4 = 0.0125 a/3 = 0.0167 a/2 = 0.025 a/1 = 0.05
Decision: Reject , Reject, Accept→ Accept Accept
Hochberg’s (Step-Up) Method [39]
• Step-Up: Start with largest P-value.
• If P(K)  a, then reject all null hypotheses and
stop.
• If not, accept the first null hypothesis [correspond-
ing to P(K)] and compare P(K - 1) with a/2.
• If P(K - 1)  a/2, reject all remaining null
hypotheses and stop.
• Otherwise, this second null hypothesis is accepted.
• Compare P(K - 2) with a/3 in like fashion.
Ordered
P-values:
P(1) = 0.006 P(2) = 0.011 P(3) = 0.018 P(4) = 0.021 P(5) = 0.20
a/, . . . ,
a/2,a =
a/5 = 0.01 a/4 = 0.0125 a/3 = 0.0167 a/2 = 0.025 a/1 = 0.05
Decision: Reject Reject Reject ←Reject ←Accept
If interest centers on the difference in the mean
change between treatments across time instead of at a
specific time, then a summary measure of the domain
scores can be created and a statistical difference
between a pair of treatments tested using a multiple
comparisons procedure like Hochberg’s (Step-Up)
Method.
Another way of handling multiple end points sta-
tistically is collective multiple testing, such as O’Brien’s
global test, to produce a single test of hypothesis.
Similarly, one might use multivariate hypothesis testing
such as Hotelling’s T2 or multivariate analysis of vari-
ance (MANOVA) [40–42]. We caution against using
MANOVA, however, because it requires complete data
which is rarely the situation in most pharmaceutical
trials. Within the realm of MANOVA, however, a
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hypothesis testing approach known as profile analysis
may be applicable in testing PRO claims. A profile
analysis is a hierarchical approach to multivariate
comparisons between treatment groups. It typically
proceeds in three steps: 1) a test for overall differences
in average values; 2) a test for equality of levels; and 3)
a test for differences over time. Collectively, the profile
analysis represents a complete picture of the results.
Again, the importance of a priori hypothesis specifica-
tion is vital to the appropriate application of these
statistical techniques.
Blinding
The absence of blinding (masking) of subjects to treat-
ment group assignments is frequently raised as a
potential source of bias for PROs, because subjects
may believe that the newer treatment is somehow
better and therefore may report improved health out-
comes, even in situations in which they do not feel
better. When possible, we recommend masking sub-
jects to treatment and completely avoiding this pos-
sible source of bias in PROs. Sometimes, it is not
possible to mask treatment assignments, but often in
these situations two (or more) active treatments are
evaluated in the clinical trial. In this case, it is impor-
tant to make sure that the PRO assessments are per-
formed before any clinical assessments or procedures
are undertaken which might influence patient percep-
tions of their health state, and care must be taken to
evaluate whether bias may be present. For the assess-
ment of bias, it is important to examine whether the
patient reports of symptom or health status improve-
ment are tracking with objective clinical measures and
clinician reports of change in clinical status. This bias
in patient reporting may be most critical for short-term
studies, as it may be difficult for subjects to continue to
report improved symptoms and health-related QOL in
the absence of any real effect over longer periods of
time (i.e., the initial expectations for benefits may wear
off with increased experience of no benefit).
Choosing the Correct PRO End Point
Much statistical literature has appeared about whether
changes from baseline, average values at a particular
time point, or percentage of successes should form the
basis for analysis to compare treatment regimens.
Although different statistical significance levels are
possible for each of these three types of analyses, in
most settings, analyses should result in consistent inter-
pretations with respect to treatment efficacy. As an
example, see the study by Rummans and colleagues of
a psychosocial intervention which indicated statistical
significance for all three end points [43]. Again, the a
priori research hypothesis should be the primary
source for the decision as to which end point is the
most appropriate in a given situation.
As mentioned earlier, the intention to treat principle
can be applied to identify a patient as a “success” or
“failure” with respect to treatment outcome. This
approach may be desirable if dichotomous outcomes
are reasonable or where analysts expect to have many
study dropouts (i.e., metastatic cancer). Otherwise,
continuous end points such as average values per treat-
ment (whether at a given time point or change from
baseline) may be preferred to keep the sensitivity of
a continuous end point. Change from baseline end
points typically take precedence over average values at
a given time point if researchers believe that treatment
efficacy is related to baseline values. For an analysis of
covariance model with baseline PRO as the covariate
and treatment group as the key explanatory variable,
the treatment effect and its standard error will be iden-
tical whether the dependent variable is the follow-up
PRO or change in PRO from baseline.
Sensitivity Analyses
Sensitivity analyses are not always needed or required
when conducting statistical analysis of PRO data. In
some situations, properly conceived sensitivity analy-
ses can help support and confirm the findings from the
primary PRO data analysis. Most frequently, sensitiv-
ity analyses are recommended when the level of
missing data is high (>20%), when a generally
accepted method for imputing missing PRO data is
lacking, or the best method for imputing missing PRO
data is uncertain [44].
The planned sensitivity analyses should directly
inform and address this uncertainty and the problems
associated with missing PRO data. The sensitivity
analyses can incorporate different approaches to
imputing missing PRO data, such as substituting the
worst possible (or observed) score for missing data,
multiple imputation, and other methods [23]. Alterna-
tively, different and somewhat more complicated sta-
tistical models, such as the family of pattern mixture
models or selection models [11,24] can be used to
compare the effects of treatment on PRO end points. It
is best to complete a small, focused number of sensi-
tivity analyses that are relevant and fit the particular
situation and that help address any uncertainty related
to the PRO analysis and findings. If these alternative
imputation and statistical analysis strategies produce
results that are similar to those of the primary PRO
data analysis, the findings are further supported and
confirmed. If the results of the sensitivity analyses are
disparate with the primary PRO data analysis, then
some question remains about the PRO results, and the
investigators may need to provide further explanation
for the PRO results.
Large clinical trials often include multiple clinical
sites in potentially many different countries. Hence,
using translated versions of the PRO of interest is
common practice. Translations of the PRO measures
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should be conducted according to standardized,
accepted methods with cognitive testing (linguistic
validation) of the translated measure in the countries
where the measure will be used.
Analysts should test for interaction of treatment with
study site, country, or region to provide statistical assur-
ance that the translations of the PRO did not differ
across sites by treatment group. “Revalidation” of the
PRO in each country or region to examine its psycho-
metric properties is not necessary. In a randomized
clinical trial, any differences in the PRO from country to
country will incorporate more noise in the measure-
ment and, hence, decrease the ability to detect differ-
ences between treatments. There should be no reason
that any decreased sensitivity of a PRO that has not
been ideally translated would differ between random-
ized groups any more than a clinical measure would,
and the test of interaction will provide this assurance.
How Should Null Results Be Interpreted?
Patient-reported outcome measures often include
several different domains or summary scores. Positive
treatment effects may be found in only a subset of these
domain scores. The question then arises as to how
to interpret so-called “null” results for scores that do
not demonstrate statistically significant differences
between treatment groups. The problem of how to
interpret null results is not unique to PROs. It also
arises with composite clinical end points where statis-
tical power is often inadequate to show a statistically
significant improvement in each individual component
of a composite end point. Another example concerns
different bacterial or viral subtypes in a clinical efficacy
trial of a composite vaccine, where the end point will
typically be infections caused by any of the types in the
vaccine. The sample size is often insufficient to expect
statistical significance for each subtype separately.
To approach the problem of interpreting null
results, investigators should begin by appropriately
prespecifying the hypotheses to be tested, the order in
which they are to be tested, and any multiplicity
adjustments. The choice of method and the ordering
of the hypotheses to be tested are determined by the
study objectives and by the power for different hy-
pothesis tests. With the proper prespecified statistical
hypothesis-testing plan, the interpretation of null
results is greatly clarified. Hypothesis-testing plans are
designed to preserve the overall Type I (alpha) error
while providing adequate power for meaningful tests
of a limited set of multiple hypotheses.
When data from a clinical trial are analyzed one
should claim only what one can demonstrate with
convincing supportive data. Null results are reported
in the clinical study report and should also be
addressed in journal publications. The question of
whether they would need to be mentioned in drug
labeling would depend on their importance for inter-
preting the positive results that have been shown. Null
results that call into question the validity of positive
results (e.g., those demonstrating an actual negative
effect of the treatment) would need to be interpreted
differently from secondary end points that simply
failed to achieve statistical significance in the particu-
lar order of hypothesis-testing used in the trial. For
example, clinical trials of new treatments for rheuma-
toid arthritis often find that new treatments demon-
strate significant improvements in the SF-36 physical
component but not, as expected, in the mental com-
ponent. The labels for recently approved rheumatoid
arthritis treatments (i.e., Remicaid, Enbrel, Humira)
include statements on the treatment effects on both
the physical summary and mental health summary
measures.
In general, ensuring fair and complete reporting
of PRO end points based on a clinical development
program for a new medication is imperative. The focus
should be primarily on prespecified PRO end points
and those end points that reach statistical and clinical
significance criteria. The sample sizes should allow for
sufficient power to detect differences if these differ-
ences actually exist between the study treatments. In
addition, investigators must provide sufficient evidence
and rationale supporting the selection of PRO mea-
sures for the clinical trials, because measures with poor
psychometric characteristics that do not adequately
cover the relevant PRO domains are unlikely to detect
treatment-related differences. Nevertheless, even with
psychometrically sound measures, a priori specifica-
tion of primary PRO end points, and well-designed
clinical trials, unexpected patterns of findings may
emerge. In these situations, investigators should report
all the prespecified PRO end points, whether or not
they support the treatment.
The problem of how to interpret null results is
not unique to PRO measures. The approach to inter-
pretation is greatly clarified by clear specification of
the statistical hypothesis-testing and multiplicity-
adjustment framework. Null results that call into
question the validity of positive results need to be
interpreted differently from those that simply represent
hypotheses for which statistical significance was not
achieved in the particular testing plan used in the trial.
A specific example of this, in a nonlabeling
setting, involved a psychosocial intervention designed
to impact overall patient health-related QOL [43].
Although other domains of QOL were included, the
primary testing and analysis was carried out on overall
QOL because it was the treatment target. The results
indicated that overall QOL was indeed impacted by
the intervention, although none of the other subdo-
mains of QOL changed significantly.
In a similar fashion, if different aspects of fatigue
were measured for a labeling claim, it would be the
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sponsor’s responsibility to define, a priori, which
aspects of fatigue would be likely to be impacted.
Ultimately, whether one end point is selected as primary,
or multiple coprimaries are selected, it must be support-
able by scientific argument a priori. Post hoc multiple
testing should not be allowed under any circumstances
to dredge the data for potential labeling claims.
Conclusions
Statistical analysis and interpretation related to results
based on PROs can support a labeling claim with the
same scientific integrity that is achievable for other end
points, as long as the design elements necessary for
credibility delineated in earlier manuscripts in this
series are incorporated into the clinical trials. PRO
data should be handled and viewed like any other
effectiveness data in clinical trials.
The statistical analysis plan must be clear and
consistent in justifying the various assumptions and
processes used. It is critical to specify a priori what
primary end point(s) will form the basis of the statis-
tical analysis of the claim. Particular importance needs
to be paid to the handling of missing data, the multi-
plicity of end points, and the longitudinal data struc-
ture. Methods for dealing with many of these
analytical issues now exist and guidelines for their
appropriate use are available. The FDA guidance
document appropriately indicated that, methodologi-
cal advances aside, there is need for further explor-
atory and confirmatory research in some areas. A body
of evidence is accumulating, as articulated in this
manuscript, that will continue to provide exemplary
applications for statistical analysis and interpretation
of PRO assessment in clinical trials.
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